Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2022-09-16 00:00:00 ET · period of report 2022-09-15 · accession 0000886163-22-000122 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-09-16 | 2022-09-15+ | LGND | HIGGINS JOHN L | CEO, Dir | S - Sale | $89.61 | -5,000 | 364.2K | -1% | -$448.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-15 | S | D | 2,000 | $90.00 | 367,180 | D | — | — | |
| 2 | Common | Common Stock | 2022-09-16 | S | D | 3,000 | $89.35 | 364,180 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.05 to $90.00, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |